Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Short term Debt (2016 - 2024)

Historic Short term Debt for Regen BioPharma (RGBPP) over the last 9 years, with Q2 2024 value amounting to $800149.0.

  • Regen BioPharma's Short term Debt rose 1.86% to $800149.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $800149.0, marking a year-over-year increase of 1.86%. This contributed to the annual value of $800000.0 for FY2023, which is 833.33% up from last year.
  • According to the latest figures from Q2 2024, Regen BioPharma's Short term Debt is $800149.0, which was up 1.86% from $800000.0 recorded in Q1 2024.
  • In the past 5 years, Regen BioPharma's Short term Debt ranged from a high of $66.8 million in Q1 2022 and a low of $266667.0 during Q3 2020
  • Moreover, its 5-year median value for Short term Debt was $800000.0 (2020), whereas its average is $4.4 million.
  • Its Short term Debt has fluctuated over the past 5 years, first skyrocketed by 1897920.86% in 2022, then tumbled by 9880.2% in 2023.
  • Over the past 5 years, Regen BioPharma's Short term Debt (Quarter) stood at $350000.0 in 2020, then soared by 133.24% to $816327.0 in 2021, then grew by 0.51% to $820513.0 in 2022, then dropped by 2.5% to $800000.0 in 2023, then grew by 0.02% to $800149.0 in 2024.
  • Its Short term Debt was $800149.0 in Q2 2024, compared to $800000.0 in Q1 2024 and $800000.0 in Q4 2023.